{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:59:17Z","timestamp":1792519157909,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cholangiocarcinoma (CCA) comprises a heterogeneous group of biliary malignant tumors with poor prognosis and limited therapeutic options. Recent studies have highlighted the role of the immune system in the development and progression of intrahepatic CCA (iCCA). In this study, we investigated the role of the scavenger receptor MARCO in iCCA. Employing transcriptomic, spatial proteomic and histological analyses of human samples, MARCO was found on a specific subtype of tumor-associated macrophages linked to immunosuppression and extracellular matrix remodeling within the tumor microenvironment. High MARCO expression in human iCCA tumors correlated with worse overall survival, T cell dysfunction and increased collagen deposition. In line with this, MARCO expression was associated with a T\n                    <jats:sub>H<\/jats:sub>\n                    2-skewed immune response and was increased in macrophages exposed to IL-4 and IL-13.\n                    <jats:italic>Marco<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u2212\/\u2212<\/jats:italic>\n                    <\/jats:sup>\n                    mice were protected against iCCA development, exhibiting reduced tumor burden, fewer innate immune cells related to T\n                    <jats:sub>H<\/jats:sub>\n                    2 responses and attenuated fibrosis. Moreover,\n                    <jats:italic>Marco<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u2212\/\u2212<\/jats:italic>\n                    <\/jats:sup>\n                    mice exhibited lower levels of immunosuppressive markers on macrophages and cytotoxic T cells, resulting in improved overall survival and reduced lung metastases in an orthotopic tumor model. The use of an anti-MARCO antibody further reduced tumor volume in wild-type mice. This study identifies MARCO as a key regulator of immunosuppression, fibrosis and tumor progression in iCCA, and supports its potential as a novel therapeutic target for macrophage-directed immunotherapy.\n                  <\/jats:p>","DOI":"10.1038\/s41392-026-02657-w","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:03:22Z","timestamp":1777421002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growth"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-1423","authenticated-orcid":false,"given":"Alo\u00f1a","family":"Agirre-Lizaso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maider","family":"Huici-Izagirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm J.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Zhuravleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8570-2519","authenticated-orcid":false,"given":"Guido","family":"Carpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-8903","authenticated-orcid":false,"given":"Diletta","family":"Overi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu","family":"Urretabizkaia-Garmendia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibone","family":"Labiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6551-6727","authenticated-orcid":false,"given":"Ana","family":"Korosec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Val","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-8567","authenticated-orcid":false,"given":"Diego F.","family":"Calvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-3003","authenticated-orcid":false,"given":"Sumera I.","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4421-6917","authenticated-orcid":false,"given":"Joke M. M.","family":"den Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3553-1755","authenticated-orcid":false,"given":"Patricia","family":"Aspichueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hijona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaida","family":"La Casta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Jim\u00e9nez-Ag\u00fcero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0561-7902","authenticated-orcid":false,"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-0326","authenticated-orcid":false,"given":"Rocio I. R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"European CCA Histology Registry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-5244","authenticated-orcid":false,"given":"Jesper B.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7490-8009","authenticated-orcid":false,"given":"Gernot","family":"Schabbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-9968","authenticated-orcid":false,"given":"Luis","family":"Bujanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6193-7436","authenticated-orcid":false,"given":"Pedro M.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-2343","authenticated-orcid":false,"given":"Omar","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5224-2373","authenticated-orcid":false,"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-0972","authenticated-orcid":false,"given":"Maria J.","family":"Perugorria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2657_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557\u2013588 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2657_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal, I. D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 76, 182\u2013188 (2020).","journal-title":"Histopathology"},{"key":"2657_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez, L. et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J. Hepatol. 76, 1109\u20131121 (2022).","journal-title":"J. Hepatol."},{"key":"2657_CR4","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.3390\/jcm10132820","volume":"10","author":"S Langella","year":"2021","unstructured":"Langella, S. et al. Recurrence after curative resection for intrahepatic cholangiocarcinoma: how to predict the chance of repeat hepatectomy? J. Clin. Med. 10, 2820 (2021).","journal-title":"J. Clin. Med."},{"key":"2657_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"D-Y Oh","year":"2022","unstructured":"Oh, D.-Y. et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol. Hepatol. 7, 522\u2013532 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2657_CR6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"2657_CR7","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris","year":"2024","unstructured":"Burris, H. A. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 25, 626\u2013635 (2024).","journal-title":"Lancet Oncol."},{"key":"2657_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","volume":"72","author":"MA Martin-Serrano","year":"2023","unstructured":"Martin-Serrano, M. A. et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 72, 736\u2013748 (2023).","journal-title":"Gut"},{"key":"2657_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/liv.14098","volume":"39","author":"L Fabris","year":"2019","unstructured":"Fabris, L. et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 39, 63\u201378 (2019).","journal-title":"Liver Int."},{"key":"2657_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361 (2014).","journal-title":"Immunity"},{"key":"2657_CR11","doi-asserted-by":"publisher","first-page":"771488","DOI":"10.3389\/fonc.2021.771488","volume":"11","author":"B Shi","year":"2021","unstructured":"Shi, B. et al. The scavenger receptor MARCO expressed by tumor-associated macrophages are highly associated with poor pancreatic cancer prognosis. Front. Oncol. 11, 771488 (2021).","journal-title":"Front. Oncol."},{"key":"2657_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00906-x","volume":"13","author":"AX Chen","year":"2021","unstructured":"Chen, A. X. et al. Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker. Genome Med. 13, 88 (2021).","journal-title":"Genome Med."},{"key":"2657_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/path.2278","volume":"214","author":"A Bergamaschi","year":"2008","unstructured":"Bergamaschi, A. et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 214, 357\u2013367 (2008).","journal-title":"J. Pathol."},{"key":"2657_CR14","doi-asserted-by":"publisher","first-page":"216568","DOI":"10.1016\/j.canlet.2023.216568","volume":"582","author":"L Ding","year":"2024","unstructured":"Ding, L. et al. Blocking MARCO+ tumor-associated macrophages improves anti-PD-L1 therapy of hepatocellular carcinoma by promoting the activation of STING-IFN type I pathway. Cancer Lett. 582, 216568 (2024).","journal-title":"Cancer Lett."},{"key":"2657_CR15","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.celrep.2016.04.084","volume":"15","author":"A-M Georgoudaki","year":"2016","unstructured":"Georgoudaki, A.-M. et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 15, 2000\u20132011 (2016).","journal-title":"Cell Rep."},{"key":"2657_CR16","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41586-024-07372-6","volume":"629","author":"Y Miyamoto","year":"2024","unstructured":"Miyamoto, Y. et al. Periportal macrophages protect against commensal-driven liver inflammation. Nature 629, 901\u2013909 (2024).","journal-title":"Nature"},{"key":"2657_CR17","doi-asserted-by":"publisher","first-page":"e151037","DOI":"10.1172\/jci.insight.151037","volume":"7","author":"D Xu","year":"2022","unstructured":"Xu, D. et al. PLG nanoparticles target fibroblasts and MARCO+ monocytes to reverse multiorgan fibrosis. JCI Insight 7, e151037 (2022).","journal-title":"JCI Insight"},{"key":"2657_CR18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2011.12.005","volume":"142","author":"JB Andersen","year":"2012","unstructured":"Andersen, J. B. et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142, 1021\u20131031 (2012).","journal-title":"Gastroenterology"},{"key":"2657_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/hep.30816","volume":"71","author":"CJ O\u2019Rourke","year":"2020","unstructured":"O\u2019Rourke, C. J. et al. Identification of a pan-gamma-secretase inhibitor response signature for notch-driven cholangiocarcinoma. Hepatology 71, 196\u2013213 (2020).","journal-title":"Hepatology"},{"key":"2657_CR20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/hep.31092","volume":"72","author":"S Job","year":"2020","unstructured":"Job, S. et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 72, 965\u2013981 (2020).","journal-title":"Hepatology"},{"key":"2657_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","volume":"32","author":"J Chaisaingmongkol","year":"2017","unstructured":"Chaisaingmongkol, J. et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32, 57\u201370.e3 (2017).","journal-title":"Cancer Cell"},{"key":"2657_CR22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul, A. et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7, 1116\u20131135 (2017).","journal-title":"Cancer Discov."},{"key":"2657_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","volume":"40","author":"L Dong","year":"2022","unstructured":"Dong, L. et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 40, 70\u201387.e15 (2022).","journal-title":"Cancer Cell"},{"key":"2657_CR24","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1016\/j.cell.2023.08.019","volume":"186","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. An immune cell atlas reveals the dynamics of human macrophage specification during prenatal development. Cell 186, 4454\u20134471.e19 (2023).","journal-title":"Cell"},{"key":"2657_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cell.2021.12.018","volume":"185","author":"M Guilliams","year":"2022","unstructured":"Guilliams, M. et al. Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell 185, 379\u2013396.e38 (2022).","journal-title":"Cell"},{"key":"2657_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","volume":"51","author":"C-A Dutertre","year":"2019","unstructured":"Dutertre, C.-A. et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity 51, 573\u2013589.e8 (2019).","journal-title":"Immunity"},{"key":"2657_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08278-x","volume":"12","author":"B Chen","year":"2022","unstructured":"Chen, B., Li, R., Kubota, A., Alex, L. & Frangogiannis, N. G. Identification of macrophages in normal and injured mouse tissues using reporter lines and antibodies. Sci. Rep. 12, 4542 (2022).","journal-title":"Sci. Rep."},{"key":"2657_CR28","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1158\/1078-0432.CCR-11-1107","volume":"17","author":"TR Sippel","year":"2011","unstructured":"Sippel, T. R. et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin. Cancer Res. 17, 6992\u20137002 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2657_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","volume":"117","author":"A Taylor","year":"2006","unstructured":"Taylor, A., Verhagen, J., Blaser, K., Akdis, M. & Akdis, C. A. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 117, 433\u2013442 (2006).","journal-title":"Immunology"},{"key":"2657_CR30","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1182\/blood.V95.6.2157","volume":"95","author":"V Terpstra","year":"2000","unstructured":"Terpstra, V. & van Berkel, T. J. Scavenger receptors on liver Kupffer cells mediate the in vivo uptake of oxidatively damaged red blood cells in mice. Blood 95, 2157\u20132163 (2000).","journal-title":"Blood"},{"key":"2657_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/j.2040-4603.2013.tb00510.x","volume":"3","author":"LJ Dixon","year":"2013","unstructured":"Dixon, L. J., Barnes, M., Tang, H., Pritchard, M. T. & Nagy, L. E. Kupffer cells in the liver. Compr. Physiol. 3, 785\u2013797 (2013).","journal-title":"Compr. Physiol."},{"key":"2657_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00795-003-0228-x","volume":"37","author":"M Naito","year":"2004","unstructured":"Naito, M., Hasegawa, G., Ebe, Y. & Yamamoto, T. Differentiation and function of Kupffer cells. Med. Electron Microsc. 37, 16\u201328 (2004).","journal-title":"Med. Electron Microsc."},{"key":"2657_CR33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.bbadis.2017.06.006","volume":"1864","author":"AP Mansini","year":"2018","unstructured":"Mansini, A. P. et al. The cholangiocyte primary cilium in health and disease. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1245\u20131253 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"2657_CR34","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1158\/0008-5472.CAN-18-3560","volume":"79","author":"A Jim\u00e9nez-S\u00e1nchez","year":"2019","unstructured":"Jim\u00e9nez-S\u00e1nchez, A., Cast, O. & Miller, M. L. Comprehensive benchmarking and integration of tumor microenvironment cell estimation methods. Cancer Res. 79, 6238\u20136246 (2019).","journal-title":"Cancer Res."},{"key":"2657_CR35","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang, P. et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med. 24, 1550\u20131558 (2018).","journal-title":"Nat. Med."},{"key":"2657_CR36","doi-asserted-by":"publisher","first-page":"6575","DOI":"10.1158\/0008-5472.CAN-18-0689","volume":"78","author":"L Xu","year":"2018","unstructured":"Xu, L. et al. TIP: a web server for resolving tumor immunophenotype profiling. Cancer Res. 78, 6575\u20136580 (2018).","journal-title":"Cancer Res."},{"key":"2657_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12014-019-9257-x","volume":"16","author":"G Carpino","year":"2019","unstructured":"Carpino, G. et al. Matrisome analysis of intrahepatic cholangiocarcinoma unveils a peculiar cancer-associated extracellular matrix structure. Clin. Proteom. 16, 37 (2019).","journal-title":"Clin. Proteom."},{"key":"2657_CR38","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/hep.27687","volume":"61","author":"D Yamada","year":"2015","unstructured":"Yamada, D. et al. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology 61, 1627\u20131642 (2015).","journal-title":"Hepatology"},{"key":"2657_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add8945","volume":"8","author":"T Fabre","year":"2023","unstructured":"Fabre, T. et al. Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation. Sci. Immunol. 8, eadd8945 (2023).","journal-title":"Sci. Immunol."},{"key":"2657_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2015.05.010","volume":"75","author":"J Zhu","year":"2015","unstructured":"Zhu, J. T. helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine 75, 14\u201324 (2015).","journal-title":"Cytokine"},{"key":"2657_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.canlet.2004.07.027","volume":"219","author":"Y Tanimura","year":"2005","unstructured":"Tanimura, Y. et al. Tumor necrosis factor alpha promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2. Cancer Lett. 219, 205\u2013213 (2005).","journal-title":"Cancer Lett."},{"key":"2657_CR42","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jhep.2019.05.027","volume":"71","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. J. Hepatol. 71, 742\u2013752 (2019).","journal-title":"J. Hepatol."},{"key":"2657_CR43","doi-asserted-by":"publisher","first-page":"e92902","DOI":"10.1172\/jci.insight.92902","volume":"2","author":"M Itoh","year":"2017","unstructured":"Itoh, M. et al. CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis. JCI Insight 2, e92902 (2017).","journal-title":"JCI Insight"},{"key":"2657_CR44","doi-asserted-by":"publisher","first-page":"32005","DOI":"10.1073\/pnas.2015343117","volume":"117","author":"S Eisinger","year":"2020","unstructured":"Eisinger, S. et al. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proc. Natl. Acad. Sci. USA 117, 32005\u201332016 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2657_CR45","doi-asserted-by":"publisher","first-page":"e20210564","DOI":"10.1084\/jem.20210564","volume":"219","author":"M Masetti","year":"2022","unstructured":"Masetti, M. et al. Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. J. Exp. Med. 219, e20210564 (2022).","journal-title":"J. Exp. Med."},{"key":"2657_CR46","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jhep.2022.11.005","volume":"78","author":"J Merters","year":"2023","unstructured":"Merters, J. & Lamarca, A. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. J. Hepatol. 78, 652\u2013657 (2023).","journal-title":"J. Hepatol."},{"key":"2657_CR47","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio, M. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann. Oncol. 33, 929\u2013938 (2022).","journal-title":"Ann. Oncol."},{"key":"2657_CR48","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"2657_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03813-w","volume":"20","author":"M Liu","year":"2022","unstructured":"Liu, M., Liu, L., Song, Y., Li, W. & Xu, L. Targeting macrophages: a novel treatment strategy in solid tumors. J. Transl. Med. 20, 586 (2022).","journal-title":"J. Transl. Med."},{"key":"2657_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103375","volume":"67","author":"M Zhou","year":"2021","unstructured":"Zhou, M. et al. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine 67, 103375 (2021).","journal-title":"EBioMedicine"},{"key":"2657_CR51","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jhep.2022.05.043","volume":"77","author":"G Alvisi","year":"2022","unstructured":"Alvisi, G. et al. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. J. Hepatol. 77, 1359\u20131372 (2022).","journal-title":"J. Hepatol."},{"key":"2657_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/HEP.0000000000001138","volume":"82","author":"G Fan","year":"2025","unstructured":"Fan, G. et al. The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 82, 25\u201341 (2025).","journal-title":"Hepatology"},{"key":"2657_CR53","doi-asserted-by":"publisher","first-page":"117080","DOI":"10.1016\/j.biopha.2024.117080","volume":"177","author":"S Hua","year":"2024","unstructured":"Hua, S. et al. Tumor-infiltrating T lymphocytes: a promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma. Biomed. Pharmacother. 177, 117080 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"2657_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06888-z","volume":"15","author":"D Li","year":"2024","unstructured":"Li, D. et al. Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma. Cell Death Dis. 15, 498 (2024).","journal-title":"Cell Death Dis."},{"key":"2657_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan, Z. et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol. Cancer 22, 48 (2023).","journal-title":"Mol. Cancer"},{"key":"2657_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1039\/D1MO00519G","volume":"18","author":"U Chalise","year":"2022","unstructured":"Chalise, U. et al. Macrophages secrete murinoglobulin-1 and galectin-3 to regulate neutrophil degranulation after myocardial infarction. Mol. Omics 18, 186\u2013195 (2022).","journal-title":"Mol. Omics"},{"key":"2657_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark. Res. 8, 49 (2020).","journal-title":"Biomark. Res."},{"key":"2657_CR58","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","volume":"10","author":"A Xia","year":"2019","unstructured":"Xia, A., Zhang, Y., Xu, J., Yin, T. & Lu, X.-J. T cell dysfunction in cancer immunity and immunotherapy. Front. Immunol. 10, 1719 (2019).","journal-title":"Front. Immunol."},{"key":"2657_CR59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","volume":"575","author":"P Ramachandran","year":"2019","unstructured":"Ramachandran, P. et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512\u2013518 (2019).","journal-title":"Nature"},{"key":"2657_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.matbio.2018.01.024","volume":"75\u201376","author":"M Vizovi\u0161ek","year":"2019","unstructured":"Vizovi\u0161ek, M., Fonovi\u0107, M. & Turk, B. Cysteine cathepsins in extracellular matrix remodeling: extracellular matrix degradation and beyond. Matrix Biol. 75\u201376, 141\u2013159 (2019).","journal-title":"Matrix Biol."},{"key":"2657_CR61","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3389\/fimmu.2020.00512","volume":"11","author":"TN Wight","year":"2020","unstructured":"Wight, T. N. et al. Versican\u2014a critical extracellular matrix regulator of immunity and inflammation. Front. Immunol. 11, 512 (2020).","journal-title":"Front. Immunol."},{"key":"2657_CR62","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.3390\/ijms19092676","volume":"19","author":"KM Larsen","year":"2018","unstructured":"Larsen, K. M., Minaya, M. K., Vaish, V. & Pe\u00f1a, M. M. O. The role of IL-33\/ST2 pathway in tumorigenesis. Int. J. Mol. Sci. 19, 2676 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2657_CR63","doi-asserted-by":"publisher","first-page":"e1005508","DOI":"10.1080\/2162402X.2015.1005508","volume":"4","author":"MS Maddur","year":"2015","unstructured":"Maddur, M. S. & Bayry, J. B cells drive Th2 responses by instructing human dendritic cell maturation. Oncoimmunology 4, e1005508 (2015).","journal-title":"Oncoimmunology"},{"key":"2657_CR64","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/hep.26108","volume":"57","author":"MJ Perugorria","year":"2013","unstructured":"Perugorria, M. J. et al. Tumor progression locus 2\/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice. Hepatology 57, 1238\u20131249 (2013).","journal-title":"Hepatology"},{"key":"2657_CR65","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/hep.23403","volume":"51","author":"I Uriarte","year":"2010","unstructured":"Uriarte, I. et al. Bicarbonate secretion of mouse cholangiocytes involves Na(+)-HCO(3)(-) cotransport in addition to Na(+)-independent Cl(-)\/HCO(3)(-) exchange. Hepatology 51, 891\u2013902 (2010).","journal-title":"Hepatology"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02657-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02657-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02657-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:03:23Z","timestamp":1777421003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02657-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2657"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02657-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}